(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 October 2019 (10.10.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/195471 A1

(51) International Patent Classification:
A61K 31/506 (2006.01) *A61P 35/04* (2006.01)
A61K 45/06 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2019/025655

(22) International Filing Date:
03 April 2019 (03.04.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/652,284	03 April 2018 (03.04.2018)	US
62/656,297	11 April 2018 (11.04.2018)	US
62/657,605	13 April 2018 (13.04.2018)	US
62/741,683	05 October 2018 (05.10.2018)	US

(71) Applicant: **BLUEPRINT MEDICINES CORPORATION** [US/US]; 45 Sidney Street, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **EVANS RAAB, Erica**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US). **WOLF, Beni B.**; 45 Sidney Street, Cambridge, Massachusetts 02139 (US).


(74) Agent: **PROCTOR, Amy C.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001-4413 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: RET INHIBITOR FOR USE IN TREATING CANCER HAVING A RET ALTERATION

FIG. 6A



(57) Abstract: Disclosed herein is the treatment of a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 300 mg to 400 mg of the selective RET inhibitor once daily.

WO 2019/195471 A1

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*